News

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

  • - Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D'Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD -
    05/20/2025

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

  • Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer.
    05/07/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Bright Minds Biosciences Inc. (DRUG) can sell. Click on Rating Page for detail.

The price of Bright Minds Biosciences Inc. (DRUG) is 33.63 and it was updated on 2025-08-03 01:25:56.

Currently Bright Minds Biosciences Inc. (DRUG) is in undervalued.

News
    
News

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

  • VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.
    Mon, Apr. 28, 2025

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

  • We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase.
    Wed, Apr. 16, 2025

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

  • TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
    Thu, Mar. 06, 2025

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

  • Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety.
    Sun, Jan. 26, 2025

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

  • -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an advisory capacity.
    Tue, Jan. 07, 2025
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

  • WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer.
  • 12/09/2024

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

  • The reason for the stock's rapid ascent is a mystery.
  • 11/13/2024

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

  • NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
  • 11/06/2024

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

  • VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
  • 11/04/2024

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

  • Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform targets serotonin regulation, aiming to create selective therapies with fewer side effects. DRUG's recent $35 million private placement funds Phase 2 trials, enhancing its financial outlook and potential for significant revenue if BMB-101 is successful.
  • 10/30/2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

  • LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial.
  • 10/28/2024

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

  • NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
  • 10/21/2024

Monster insider trading alert for this penny stock that rallied $3,700% in a week

  • This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed to historic levels, and it seems several investors have profited significantly from this momentum.
  • 10/19/2024

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

  • NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
  • 10/18/2024

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

  • BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program. Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls.
  • 10/16/2024

Why did this penny stock skyrocket 1,500% in a day

  • When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a meteoric rise, with minimal fundamental factors supporting this momentum.
  • 10/16/2024

Bright Minds Biosciences Stock Surges Almost 1,500%

  • Bright Minds Biosciences NASDAQ: DRUG, a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading under 1 million shares daily, the stock saw over 100 million shares change hands without any direct news.
  • 10/16/2024

Canadian psychedelics company Bright Minds shares rise 1,446% in one day

  • Yesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of psychedelics, saw its shares rocket by a frankly psychedelic-looking 1,445.8% to $38.49 from $2.50 at the start of the day.  At the request of the Canadian Investment Regulatory Organization (CIRO), Bright Minds confirmed that management "is unaware of any material changes in the company's operations that would account for the recent increase in market activity".
  • 10/16/2024

Bright Minds is Unaware of Any Material Changes

  • Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity. About Bright Minds Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
  • 10/15/2024

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

  • Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences: Neuroscience 2024 annual meeting, organized by the Society for Neuroscience (SfN), will take place in Chicago, October 5–9. Therapeutic Development at NINDS Chicago, October 7, 2024.
  • 10/03/2024

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

  • Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th. The event will feature Epilepsy KOLs to discuss the unmet needs for epilepsy treatment.
  • 09/19/2024

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

  • Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at 10:00 ET  NEW YORK , Sept.
  • 09/12/2024

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)

  • FDA confirms the favorable benefit-risk profile of WAKIX Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the next five years PLYMOUTH MEETING, Pa. , June 25, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
  • 06/25/2024

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY

  • PLYMOUTH MEETING, Pa. , June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.
  • 06/24/2024

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

  • AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary.
  • 06/11/2024

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

  • -- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
  • 08/08/2023

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

  • -- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
  • 07/20/2023

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

  • Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every five (5) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 3,772,071 common shares.
  • 07/12/2023

Bright Minds Announces Effective Date of Share Consolidation

  • VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”).
  • 07/11/2023

Penny Stocks To Buy? 10 Under $1 To Watch This Week

  • Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
  • 04/19/2023

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

  • — Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" —
  • 04/10/2023

What Is Going on With Bright Minds (DRUG) Stock Today?

  • Today's continued rally across equity markets is providing a bullish lift to many investors who have had their sentiment beat down to a great degree this year. While broad-based, certain sectors of the market are rallying more than others today.
  • 10/18/2022

Making Money With Penny Stocks When the Market Crashes

  • How to make money with penny stocks during a market crash The post Making Money With Penny Stocks When the Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/18/2022

Which Strategies Are You Using With Penny Stocks in September?

  • Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
  • 09/04/2022

Best Penny Stocks To Buy Now? 4 To Watch This Month

  • Are these penny stocks to buy now or avoid in September? The post Best Penny Stocks To Buy Now?
  • 09/02/2022

Hot Penny Stocks to Watch in the First Week of September

  • What to know about buying penny stocks today The post Hot Penny Stocks to Watch in the First Week of September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 08/29/2022

Top Strategies for Buying Penny Stocks in September? 3 to Know

  • Use these strategies for buying penny stocks in September The post Top Strategies for Buying Penny Stocks in September? 3 to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 08/28/2022

Can These Penny Stocks Explode Today? 3 to Watch

  • Here's what you need to know about buying penny stocks on August 25th The post Can These Penny Stocks Explode Today? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 08/25/2022

Why Are Psychedelics Stocks Up Today?

  • Psychedelics stocks, like Seelos Therapeutics (NASDAQ: SEEL ), Scisparc (NASDAQ: SPRC ) and Bright Minds Biosciences (NASDAQ: DRUG ), are taking off today. This morning, it was announced that the Michael J.
  • 08/24/2022

Cheap Penny Stocks to Buy in September? 3 For Your List

  • Which penny stocks are you watching right now? The post Cheap Penny Stocks to Buy in September?
  • 08/23/2022

Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public

  • Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.
  • 08/22/2022

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week

  • Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?
  • 08/18/2022

Bright Minds Biosciences: A vision for “next generation” psychedelic medicines to treat neurological conditions

  • With the COVID-19 pandemic upending life in every corner of the world and putting unwelcome pressure on people vulnerable to depression, suicide and addiction, there has never been a better time to consider new treatments for mental health challenges. One field gaining particularly rapid traction is psychedelics.
  • 11/30/2021
Unlock
DRUG Ratings Summary
DRUG Quant Ranking